Biogen (BIIB) Projected to Post Quarterly Earnings on Tuesday

Biogen (NASDAQ:BIIB - Get Free Report) is expected to release its earnings data before the market opens on Tuesday, February 11th. Analysts expect Biogen to post earnings of $3.43 per share and revenue of $2.42 billion for the quarter. Investors interested in listening to the company's conference call can do so using this link.

Biogen Trading Down 0.7 %

Shares of NASDAQ:BIIB traded down $1.02 during trading on Friday, reaching $141.35. 1,154,068 shares of the company traded hands, compared to its average volume of 1,263,660. The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.28. Biogen has a 52-week low of $139.71 and a 52-week high of $244.95. The firm has a market capitalization of $20.60 billion, a price-to-earnings ratio of 12.77, a P/E/G ratio of 1.66 and a beta of -0.08. The business's fifty day moving average is $149.53 and its 200-day moving average is $176.72.

Analyst Ratings Changes

Several equities research analysts have weighed in on BIIB shares. Truist Financial dropped their price target on shares of Biogen from $302.00 to $220.00 and set a "buy" rating for the company in a research report on Wednesday, January 8th. BMO Capital Markets lowered shares of Biogen from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $230.00 to $164.00 in a report on Friday, December 20th. Jefferies Financial Group downgraded Biogen from a "buy" rating to a "hold" rating and reduced their price target for the company from $250.00 to $180.00 in a report on Monday, December 9th. Piper Sandler cut Biogen from an "overweight" rating to a "neutral" rating and dropped their price objective for the stock from $315.00 to $138.00 in a report on Thursday, January 2nd. Finally, StockNews.com cut Biogen from a "strong-buy" rating to a "buy" rating in a research note on Saturday, December 28th. Sixteen equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $228.80.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.